Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...

Toyota's buyout deal is a bigger win for Elliott than for governance Toyota's decision to further sweeten its bid for group company Toyota Industries marks a win for activist fund Elliott Investment ...

Farran Powell is the managing editor of investing at Forbes Advisor. She was previously the assistant managing editor of investing at U.S. News & World Report. Her work has appeared in numerous ...

Target will stop selling cereals with certified synthetic colors across all stores and online by the end of May. The move reflects rising consumer demand for cleaner ingredients and builds on Target’s ...